# United Therapeutics to Present New Clinical Data at CHEST 2026 Meeting

- URL: https://stocks.freetheai.org/news/united-therapeutics-to-present-new-clinical-data-at-chest-2026-meeting-795e82
- Published: 2026-10-13T11:00:00Z
- Category: company_news; sentiment: neutral; impact: medium
- Symbols: [NASDAQ:UTHR](https://stocks.freetheai.org/symbols/NASDAQ-UTHR)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

United Therapeutics Corporation (UTHR) announced it will deliver seven presentations at the CHEST 2026 Annual Meeting in Phoenix, Arizona, scheduled for October 18-21, 2026. The presentations comprise two oral sessions and five poster presentations focused on the company's treatment portfolio for rare and severe lung diseases, including pulmonary arterial hypertension, interstitial lung disease, and idiopathic pulmonary fibrosis.

The company will also host a dedicated symposium showcasing preliminary results from the PHINDER study, which aims to improve screening tools for pulmonary hypertension associated with interstitial lung disease. Alongside these conference plans, United Therapeutics noted that regulators have accepted its New Drug Application for ralinepag to treat pulmonary arterial hypertension and a supplemental application for nebulized treprostinil to treat idiopathic pulmonary fibrosis. Both treatments remain under investigation and await regulatory approval.

Investors will monitor the upcoming conference presentations between October 18 and October 21 for preliminary clinical results and insights into earlier disease detection. Following the announcement, shares of United Therapeutics Corporation (UTHR) were trading at $550.10, up 0.17%.

## Key points

- United Therapeutics Corporation (UTHR) will feature two oral and five poster presentations at CHEST 2026 in Phoenix, Arizona, from October 18 to October 21.
- The presentations cover research on treatments for pulmonary arterial hypertension, interstitial lung disease, and idiopathic pulmonary fibrosis.
- The FDA has accepted drug applications for ralinepag in pulmonary arterial hypertension and nebulized treprostinil in idiopathic pulmonary fibrosis.
- Shares of United Therapeutics Corporation (UTHR) were trading at $550.10, up 0.17% following the announcement.

## Questions and answers

### When is United Therapeutics presenting data at CHEST 2026?

United Therapeutics Corporation will deliver presentations at the CHEST 2026 Annual Meeting from October 18 to October 21, 2026, in Phoenix, Arizona.

### Which drugs has the FDA accepted applications for?

The FDA accepted a New Drug Application for ralinepag to treat pulmonary arterial hypertension and a supplemental application for nebulized treprostinil for idiopathic pulmonary fibrosis. Both remain investigational.

### What lung conditions do the presentations focus on?

The scientific presentations focus on rare and progressive conditions, including pulmonary arterial hypertension, interstitial lung disease, and idiopathic pulmonary fibrosis.